Free Trial
NASDAQ:VYNE

VYNE Therapeutics (VYNE) Stock Price, News & Analysis

VYNE Therapeutics logo
$0.33 +0.01 (+4.47%)
Closing price 04:00 PM Eastern
Extended Trading
$0.33 -0.01 (-2.18%)
As of 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

About VYNE Therapeutics Stock (NASDAQ:VYNE)

Advanced

Key Stats

Today's Range
$0.30
$0.34
50-Day Range
$0.29
$1.46
52-Week Range
$0.28
$4.30
Volume
3.71 million shs
Average Volume
1.76 million shs
Market Capitalization
$8.51 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$6.25
Consensus Rating
Hold

Company Overview

VYNE Therapeutics Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
42nd Percentile Overall Score

VYNE MarketRank™: 

VYNE Therapeutics scored higher than 42% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    VYNE Therapeutics has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on no buy ratings, 3 hold ratings, and no sell ratings.

  • Upside Potential

    VYNE Therapeutics has a consensus price target of $6.25, representing about 1,769.6% upside from its current price of $0.33.

  • Amount of Analyst Coverage

    VYNE Therapeutics has only been the subject of 3 research reports in the past 90 days.

  • Read more about VYNE Therapeutics' stock forecast and price target.
  • Earnings Growth

    Earnings for VYNE Therapeutics are expected to decrease in the coming year, from ($0.97) to ($1.05) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of VYNE Therapeutics is -0.37, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of VYNE Therapeutics is -0.37, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    VYNE Therapeutics has a P/B Ratio of 0.09. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

  • Read more about VYNE Therapeutics' valuation and earnings.
  • Percentage of Shares Shorted

    6.44% of the float of VYNE Therapeutics has been sold short.
  • Short Interest Ratio / Days to Cover

    VYNE Therapeutics has a short interest ratio ("days to cover") of 0.6, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in VYNE Therapeutics has recently decreased by 36.79%, indicating that investor sentiment is improving significantly.
  • Dividend Yield

    VYNE Therapeutics does not currently pay a dividend.

  • Dividend Growth

    VYNE Therapeutics does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    6.44% of the float of VYNE Therapeutics has been sold short.
  • Short Interest Ratio / Days to Cover

    VYNE Therapeutics has a short interest ratio ("days to cover") of 0.6, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in VYNE Therapeutics has recently decreased by 36.79%, indicating that investor sentiment is improving significantly.
  • Search Interest

    Only 1 people have searched for VYNE on MarketBeat in the last 30 days. This is a decrease of -75% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, VYNE Therapeutics insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    Only 4.80% of the stock of VYNE Therapeutics is held by insiders.

  • Percentage Held by Institutions

    83.78% of the stock of VYNE Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about VYNE Therapeutics' insider trading history.
Receive VYNE Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for VYNE Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

VYNE Stock News Headlines

Buffett, Gates and Bezos Quietly Dumping Stocks—Here's Why
Imagine a bull market so powerful, every single investor became a millionaire. Not by finding the next NVIDIA or Bitcoin, but by owning a simple index fund. It sounds impossible. Yet it happened – just a short time ago. Now a legendary figure says: "Brace yourselves. It's about to happen here, in America. But fair warning – it could be the worst thing that ever happens to you." This story has received little coverage in the press. But if history repeats, it could bump tens of millions of Americans into a 7-figure net worth practically overnight.tc pixel
See More Headlines

VYNE Stock Analysis - Frequently Asked Questions

VYNE Therapeutics' stock was trading at $3.35 at the beginning of the year. Since then, VYNE shares have decreased by 90.0% and is now trading at $0.3343.

VYNE Therapeutics Inc. (NASDAQ:VYNE) issued its earnings results on Thursday, August, 14th. The company reported ($0.13) earnings per share for the quarter, topping the consensus estimate of ($0.23) by $0.10. The business earned $0.07 million during the quarter, compared to analyst estimates of $0.15 million. VYNE Therapeutics had a negative trailing twelve-month return on equity of 77.57% and a negative net margin of 8,097.69%.

VYNE Therapeutics shares reverse split on Monday, February 13th 2023.The 1-18 reverse split was announced on Monday, February 13th 2023. The number of shares owned by shareholders was adjusted after the market closes on Monday, February 13th 2023. An investor that had 100 shares of stock prior to the reverse split would have 6 shares after the split.

VYNE Therapeutics' top institutional shareholders include Acorn Capital Advisors LLC (4.84%), Adage Capital Partners GP L.L.C. (4.23%), Kennedy Capital Management LLC (3.75%) and Patient Square Capital LP (2.08%). Insiders that own company stock include Patrick G Lepore and Mutya Harsch.
View institutional ownership trends
.

Shares of VYNE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that VYNE Therapeutics investors own include NIO (NIO), Tesla (TSLA), Sorrento Therapeutics (SRNE), Advanced Micro Devices (AMD), Meta Platforms (META), Allena Pharmaceuticals (ALNA) and NVIDIA (NVDA).

Company Calendar

Last Earnings
8/14/2025
Today
9/23/2025
Next Earnings (Estimated)
11/06/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
MED - DRUGS
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:VYNE
CIK
1566044
Fax
N/A
Employees
30
Year Founded
N/A

Price Target and Rating

High Price Target
$8.00
Low Price Target
$4.50
Potential Upside/Downside
+1,769.6%
Consensus Rating
Hold
Rating Score (0-4)
2.00
Research Coverage
3 Analysts

Profitability

EPS (Trailing Twelve Months)
($0.90)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$39.83 million
Net Margins
-8,097.69%
Pretax Margin
-8,091.81%
Return on Equity
-77.57%
Return on Assets
-63.09%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
7.60
Quick Ratio
7.60

Sales & Book Value

Annual Sales
$500 thousand
Price / Sales
17.03
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$3.53 per share
Price / Book
0.09

Miscellaneous

Outstanding Shares
25,470,000
Free Float
24,249,000
Market Cap
$8.51 million
Optionable
Not Optionable
Beta
1.80
7 Energy Stocks to Buy and Hold Forever Cover

With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.

Get This Free Report

This page (NASDAQ:VYNE) was last updated on 9/23/2025 by MarketBeat.com Staff
From Our Partners